Tianqi Wang

Dr. Tianqi Wang


Research Focus & Metrics

Academic Career Length

3Years (2024-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
29 September 2024 in Nanomaterials
Verified
Journal Article
Open access
PDF file
HZHongqi Zhao
Hongqi Zhao
TWTianqi Wang
Tianqi Wang
XFXuan Fang
Xuan Fang
TXTao Xu
Tao Xu
JLJian Li
Jian Li
GSGaohong Sheng
Gaohong Sheng
MXenes nanosheets with high conductivity, hydrophilicity, and excellent reactive oxygen species (ROS) scavenging ability have shown promise in treating various degenerative diseases correlated with abnormal ROS accumulation. Herein, the therapeutic potential of Ti3C2Tx nanosheets, which is the most widely investigated MXene material, in delaying osteoarthritis (OA) progression is demonstrated. In vitro experiments indicate the strong ROS scavenging capacity of Ti3C2Tx nanosheets and their acceptable biocompatibility. Ti3C2Tx nanosheets effectively protect chondrocytes from cell death induced by oxidative stress. In addition, Ti3C2Tx nanosheets demonstrate a prominent anti-inflammatory effect and the ability to restore homeostasis between anabolic activities and catabolic activities in chondrocytes. Furthermore, RNA sequencing reveals the potential mechanism underlying the Ti3C2Tx nanosheet-mediated therapeutic effect. Finally, the in vivo curative effect of Ti3C2Tx nanosheets is verified using a rat OA model. Histological staining and immunohistochemical analyses indicate that Ti3C2Tx nanosheets effectively ameliorate OA progression. Conclusively, the in vitro and in vivo experiments suggest that Ti3C2Tx nanosheets could be a promising and effective option for OA treatment.

2 January 2025 in Burns & Trauma
Verified
Journal Article
Open access
TWTianqi Wang
Tianqi Wang
CNChiew Yong Ng
Chiew Yong Ng
BNBryan Zheng Jie Ng
Bryan Zheng Jie Ng
WTWei Seong Toh
Wei Seong Toh
James Hoi Po HuiJames Hoi Po Hui
James Hoi Po Hui
Osteoarthritis (OA) is a prevalent degenerative joint disorder with significant socioeconomic impact. Despite advances in understanding its pathophysiology, current therapeutic strategies remain largely palliative. Small extracellular vesicles (sEV) have emerged as crucial mediators of intercellular communication in joint tissues, offering new insights into OA pathogenesis and potential therapeutic targets. This review explores the application of multi-omics approaches to sEV research in OA, assessing how these advanced technologies are contributing to our understanding of the disease and their potential to revolutionize OA management. We discuss the latest findings on the role of sEV in OA, the applications of multi-omics technologies in deciphering sEV cargo, the progress toward clinical translation, and the challenges and opportunities in this field. By synthesizing current knowledge and identifying key research gaps, this review provides a roadmap for leveraging sEV multi-omics to bridge the gap between molecular discoveries and clinical applications in OA.

3 April 2026 in Journal of Orthopaedic Translation
Verified
Journal Article
Open access
JMJun Ma
Jun Ma
CCChen Chen
Chen Chen
HJHao Jiang
Hao Jiang
MXMengran Xi
Mengran Xi
WLWei Luo
Wei Luo
PYPatrick Shu-Hang YUNG
Patrick Shu-Hang YUNG
Sarcopenia and osteoarthritis are two common musculoskeletal disorders that often coexist, posing significant challenges in clinical management. These conditions share underlying mechanisms such as chronic inflammation, metabolic dysfunction, and biomechanical stress, which accelerate musculoskeletal degeneration. Sarcopenia, characterized by muscle loss and weakness, and osteoarthritis, marked by cartilage degradation and joint dysfunction, frequently overlap, leading to increased disability and reduced quality of life. The presence of both conditions creates a detrimental cycle where muscle weakness exacerbates joint pain, and joint dysfunction further weakens muscles. This comorbidity complicates treatment, requiring integrated strategies that address both muscle and joint pathology. Advances in personalized therapies, driven by multi-omics technologies, are crucial in targeting these interconnected conditions more effectively. Precision medicine, using genetic, metabolic, and physiological data, can help tailor treatments and improve patient outcomes. Furthermore, the integration of adaptive interventions, digital twin models, and real-time feedback systems will play key roles in refining individualized treatment plans. Multi-omics integration and real-world evidence are also transforming how clinical trials are designed and how we assess disease progression, moving away from structural markers to functional and patient-centered outcomes. Effective interventions must involve early detection, personalized approaches, and interdisciplinary care, aiming to break the cycle of degeneration and improve patients' functional independence and quality of life. This review identifies the biomechanical, metabolic, and epigenetic "vicious cycles" that drive the comorbidity of sarcopenia and osteoarthritis. By integrating multi-omics data, digital twin modeling, and real-time biomechanical feedback, this work provides a framework for clinical precision medicine. The clinical significance lies in identifying a "mechanical window of opportunity" for early intervention-using personalized exercise and nutritional strategies to restore joint homeostasis and prevent irreversible functional decline.

22 January 2025 in Composites Part B: Engineering
Verified
Journal Article
Open access
TWTianqi Wang
Tianqi Wang
XFXuan Fang
Xuan Fang
HZHongqi Zhao
Hongqi Zhao
YZYi Zhang
Yi Zhang
YLYuanquan Li
Yuanquan Li
JYJiyuan Yan
Jiyuan Yan

31 January 2026 in Advanced Composites and Hybrid Materials
Verified
Journal Article
Open access
PDF file
XFXuan Fang
Xuan Fang
HZHongqi Zhao
Hongqi Zhao
WKWentao Ke
Wentao Ke
YZYi Zou
Yi Zou
TXTao Xu
Tao Xu
TMTian Ma
Tian Ma
Osteoarthritis (OA) is a chronic joint disorder characterized by synovial inflammation, cartilage degradation and macrophage polarization imbalance, where excessive reactive oxygen species (ROS) accumulation and mitochondrial dysfunction exacerbate pro-inflammatory M1 macrophage polarization. Here, a pH-responsive nanocomposite (Se/LDH@PEG-M) is developed by integrating selenium (Se) within MgAl-layered double hydroxide (MgAl-LDH), modified with PEGylation and loaded with the mitochondria-targeted antioxidant Mito-TEMPO. The synthesized nanocomposite retains glutathione peroxidase (GPX)-like activity and the antioxidant capacity of Se nanoparticles, while exhibiting pH-responsive degradation to neutralize acidic OA microenvironments and release Mg²⁺, Se and Mito-TEMPO for inflammation suppression, ROS scavenging and macrophage polarization modulation. In vitro, Se/LDH@PEG-M effectively inhibits pro-inflammatory M1 polarization while promoting anti-inflammatory M2 phenotypes by suppressing multiple inflammatory pathways, restoring redox homeostasis, and enhancing mitochondrial oxidative phosphorylation and ATP production via respiratory chain activation. Conditioned medium from Se/LDH@PEG-M-treated macrophages attenuates chondrocyte apoptosis, inflammation and catabolism compared to LPS group. In murine OA models, intra-articular Se/LDH@PEG-M administration effectively alleviates synovial inflammation, suppresses osteophyte formation and mitigates cartilage degradation. This multifunctional nanocomposite concurrently targets OA pathogenesis through macrophage immunomodulation, ROS scavenging and mitochondrial protection, providing a potential therapeutic strategy for OA management. Graphical Abstract Schematic illustration of the synthesis process and therapeutic mechanism of Se/LDH@PEG-M. (A)The synthesis procedure of Se/LDH@PEG-M nanocomposites. The nanocomposites were developed by integrating selenium (Se) into Mg-Al layered double hydroxides, followed by PEG modification and loading with mitochondria-targeted antioxidant Mito-TEMPO. (B) The therapeutic mechanism of Se/LDH@PEG-M. The nanocomposites degraded in acidic OA microenvironments and releasing Mg²⁺, Se and Mito-TEMPO for inflammation suppression, ROS scavenging and immunomodulation.

9 June 2026 in Journal of Drug Delivery Science and Technology
Verified
Journal Article
Open access
TWTianqi Wang
Tianqi Wang
SJShaoze Jing
Shaoze Jing
KMKe Ma
Ke Ma
FZFan Zhang
Fan Zhang
BWBing Wang
Bing Wang
JZJun Zhang
Jun Zhang